|
1
|
Cruz GD, Ostroff JS, Kumar JV and Gajendra
S: Preventing and detecting oral cancer. Oral health care
providers' readiness to provide health behavior counseling and oral
cancer examinations. J Am Dent Assoc. 136:594–601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rogers SN, Brown JS, Woolgar JA, Lowe D,
Magennis P, Shaw RJ and Vaughan D: Survival following primary
surgery for oral cancer. Oral Oncol. 45:201–211. 2009. View Article : Google Scholar
|
|
3
|
Plati J, Bucur O and Khosravi-Far R:
Apoptotic cell signaling in cancer progression and therapy. Integr
Biol (Camb). 3:279–296. 2011. View Article : Google Scholar
|
|
4
|
Perciavalle RM and Opferman JT: Delving
deeper: MCL-1′s contributions to normal and cancer biology. Trends
Cell Biol. 23:22–29. 2013. View Article : Google Scholar
|
|
5
|
Thomas LW, Lam C and Edwards SW: Mcl-1;
the molecular regulation of protein function. FEBS Lett.
584:2981–2989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quinn BA, Dash R, Azab B, Sarkar S, Das
SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, et al:
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig
drugs. 20:1397–1411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Foretz M and Viollet B: New promises for
metformin: Advances in the understanding of its mechanisms of
action. Med Sci (Paris). 30:82–92. 2014.In French. View Article : Google Scholar
|
|
8
|
Evans JM, Donnelly LA, Emslie Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar
|
|
11
|
Landman GW, Kleefstra N, van Haterenm KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
12
|
Wang F, Xu J, Xia F, Liu Z, Zhao S, Liu H
and Jiang Z: Effects of metformin on human oral cancer KB cell
proliferation and apoptosis in vitro. Nan Fang Yi Ke Da Xue Xue
Bao. 34:159–163. 2014.In Chinese. PubMed/NCBI
|
|
13
|
Marini C, Salani B, Massollo M, Amaro A,
Esposito AI, Orengo AM, Capitanio S, Emionite L, Riondato M,
Bottoni G, et al: Direct inhibition of hexokinase activity by
metformin at least partially impairs glucose metabolism and tumor
growth in experimental breast cancer. Cell Cycle. 12:3490–3499.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mohammed A, Janakiram NB, Brewer M,
Ritchie RL, Marya A, Lightfoot S, Steele VE and Rao CV:
Antidiabetic drug metformin prevents progression of pancreatic
cancer by targeting in part cancer stem cells and mTOR signaling.
Transl Oncol. 6:649–659. 2013. View Article : Google Scholar
|
|
15
|
Miyoshi H, Kato K, Iwama H, Maeda E,
Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al:
Effect of the anti-diabetic drug metformin in hepatocellular
carcinoma in vitro and in vivo. Int J Oncol. 45:322–332.
2014.PubMed/NCBI
|
|
16
|
Melet A, Song K, Bucur O, Jagani Z,
Grassian AR and Khosravi-Far R: Apoptotic pathways in tumor
progression and therapy. Adv Exp Med Biol. 615:47–79. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Del Gaizo Moore V and Letai A: BH3
profiling-measuring integrated function of the mitochondrial
apoptotic pathway to predict cell fate decisions. Cancer Lett.
332:202–205. 2013. View Article : Google Scholar
|
|
18
|
Karnak D and Xu L: Chemosensitizaition of
prostate cancer by modulating Bcl-2 family proteins. Curr Drug
Targets. 11:699–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Yuan Y, Huang L, Qiao M and Zhang Y:
Metformin alters the expression profiles of microRNAs in human
pancreatic cancer cells. Diabetes Res Clin Pract. 96:187–195. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O'Hara SP, Mott JL, Splinter PL, Gores GJ
and LaRusso NF: MicroRNAs: Key modulators of posttranscriptional
gene expression. Gastroenterology. 136:17–25. 2009. View Article : Google Scholar
|
|
21
|
Yang X, Liang L, Zhang XF, Jia HL, Qin Y,
Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a
suppresses tumor growth and metastasis of human hepatocellular
carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology.
58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang YK, Wang H, Leng Y, Li ZL, Yang YF,
Xiao FJ, Li QF, Chen XQ and Wang LS: Overexpression of microRNA-29b
induces apoptosis of multiple myeloma cells through down regulating
Mcl-1. Biochem Biophys Res Commun. 414:233–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao J, Li L, Wu M, Liu M and Xie X, Guo J,
Tang H and Xie X: MiR-26a inhibits proliferation and migration of
breast cancer through repression of MCL-1. PLoS One. 8:e651382013.
View Article : Google Scholar : PubMed/NCBI
|
